Back to top
more

Organovo (ONVO)

(Real Time Quote from BATS)

$1.26 USD

1.26
385,280

+0.14 (12.50%)

Updated Apr 18, 2024 12:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will Organovo Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Organovo.

Zacks.com featured highlights include: Avinger, Alexion Pharmaceuticals, CyberArk Software, Organovo and Qualys

by Zacks Equity Research

Zacks.com featured highlights include: Avinger, Alexion Pharmaceuticals, CyberArk Software, Organovo and Qualys

Sanghamitra Saha headshot

What Bargain Hunting? Tap 5 Stocks With Rising P/E

by Sanghamitra Saha

Bet on these top-ranked stocks with rising P/E for outsized gains.

Organovo (ONVO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Organovo (ONVO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Organovo (ONVO) delivered earnings and revenue surprises of 0.00% and -13.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Organovo (ONVO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Options Traders Expect Huge Moves in Organovo (ONVO) Stock

by Zacks Equity Research

Organovo (ONVO) needs investors to pay close attention to the stock based on moves in the options market lately.

Organovo (ONVO) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Organovo (ONVO) delivered earnings and revenue surprises of 14.29% and -10.15%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Will Organovo (ONVO) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nitish Marwah headshot

New Strong Buy Stocks for December 14th

by Nitish Marwah

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Organovo (ONVO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Organovo (ONVO) delivered earnings and revenue surprises of 37.50% and 4.43%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Organovo (ONVO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Organovo (ONVO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Organovo (ONVO) delivered earnings and revenue surprises of 0.00% and -40.66%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    Sweta Killa headshot

    5 Top Performing Stocks of the Best ETF of May

    by Sweta Killa

    Inside the best performing stocks of the top ETF of May - ARKG.

      Can The Uptrend Continue for Organovo Holdings (ONVO)?

      by Zacks Equity Research

      Investors certainly have to be happy with Organovo Holdings, Inc. (ONVO) and its short term performance

        Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, American Superconductor and Stratasys

        by Zacks Equity Research

        Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, American Superconductor and Stratasys

          Try Rising P/E Investing With 5 Top-Ranked Stocks

          by Zacks Equity Research

          Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

            Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys

            by Zacks Equity Research

            Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys

              Keep Faith in Rising P/E: Play 5 Top-Ranked Stocks

              by Zacks Equity Research

              Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

                Zacks.com featured highlights: Fortuna Silver Mines, Ritter Pharmaceuticals , Organovo Holdings, Western Digital and Willdan Group

                by Zacks Equity Research

                Zacks.com featured highlights: Fortuna Silver Mines, Ritter Pharmaceuticals , Organovo Holdings, Western Digital and Willdan Group

                  Take the Less-Trodden Path: Rising P/E for 5 Winning Stocks

                  by Zacks Equity Research

                  Cross the age-old barrier of low P/E investing, bet on these five stocks that boast a rising P/E.

                    The Zacks Analyst Blog Highlights: Codexis, EMCORE, Intevac, Organovo Holdings and StarTek

                    by Zacks Equity Research

                    The Zacks Analyst Blog Highlights: Codexis, EMCORE, Intevac, Organovo Holdings and StarTek